Abstracts

209 – Single-Nucleotide Identification of Ultraconserved m6A Positions on HIV-1 RNA

Background N6-methyladenosine (m6A) is the most abundant internal modification of eukaryotic messenger RNA and regulates multiple RNA-related biological processes. M6A modifications of HIV-1 RNA have been reported, but hotspots and functional effects of m6A variations in HIV-1 transcripts remain poorly characterized. Methods We applied GLORI-seq to map m6A modifications at single-nucleotide resolution in 9 commonly…

491 – Optimization of Dose and Analytic Treatment Interruption for VRC07-523LS and PGT121.414.LS

Background A5388 is an ongoing phase II, randomized, double-blind, placebo-controlled study evaluating VRC07-523LS and PGT121.414.LS. These novel HIV-1 broadly neutralizing antibodies (bNAbs) are administered at antiretroviral therapy initiation in adults with acute or early HIV and an analytical treatment interruption (ATI) is planned after bNab clearance to evaluate for a vaccinal-like effect characterized by sustained virologic suppression.…

225 – Female-Predominant Anti-CD4 IgG Autoantibody in People With HIV on ART

Background Autoimmunity contributes to HIV immunopathogenesis even in the absence of overt autoimmune disease. We previously showed that anti-CD4 autoantibodies from people with HIV (PWH) on suppressive antiretroviral therapy (ART) can mediate cytotoxicity against CD4+ T cells, implicating a role in impaired immune reconstitution. Despite viral suppression, many PWH with poor CD4 recovery exhibit chronic…

516 – Once-Weekly Islatravir Plus Lenacapavir Maintains HIV-1 Suppression Through 96 Weeks: Phase II Study

Background In a Phase 2 study (NCT05052996), once-weekly oral islatravir (ISL), a nucleoside reverse transcriptase translocation inhibitor, plus lenacapavir (LEN), a capsid inhibitor, maintained a high rate (94.2%) of virologic suppression at Week (W) 48 in virologically suppressed (VS) adults with HIV-1. We report efficacy, safety, and adherence outcomes in all participants receiving ISL+LEN during…

239 – Methamphetamine Increases HIV Infection in Gut Tissue via TNF-alpha

Background Substance use, particularly stimulant drugs such as methamphetamine (MA), is associated with increased HIV incidence and disease progression. The mechanism underlying these associations is likely multifactorial, including sexual risk behavior and social networks, but also may be related to drug-induced immune effects. MA triggers both systemic and localized inflammation in a variety of tissues,…

269 – LN CXCR5+ HIV-Specific CD8 T Cells of Controllers Express GZMK to Mediate Rapid Effector Functions

Background The precise mechanisms enabling ART-free control of HIV remain to be fully elucidated. While HIV-specific CD8 T cells of HIV controllers (HIVc) are highly proliferative, the acquisition of maximal classical cytolytic potential (granzyme B, GZMB/perforin) after antigen exposure may require several days. In addition, the expression of classical cytolytic molecules may be tightly regulated in…

548 – Time to ART Initiation After HIV Acquisition in HVTN 703/HPTN 081 and HVTN 704/HPTN 085 Trials

Background The HVTN 703/HPTN 081 and HVTN 704/HPTN 085 Antibody Mediated Prevention (AMP) trials demonstrated that broadly neutralizing monoclonal antibodies (bnAbs) could prevent acquisition of bnAb-sensitive HIV-1. Ensuring timely linkage to care and antiretroviral therapy (ART) initiation for participants who acquire HIV during clinical trials is critical. However, barriers to ART initiation in HIV prevention…

282 – Enhancing ADCC Responses in HIV-1 Vaccines: CD4 Incorporation Into Virus-Like Particles (VLPs)

Background The RV144 vaccine trial correlated antibody-dependent cellular cytotoxicity (ADCC) with a reduced risk of HIV infection, highlighting the association between Fc-mediated responses and protective immunity. A promising approach to optimizing ADCC induction is to enhance the exposure of CD4-inducible (CD4i) epitopes, which are responsible for eliciting ADCC responses, on the HIV-1 envelope. These epitopes…